# Lassogen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lassogen

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.lassogen.com
- Total disclosed funding: $4.5M
- Latest round: Seed (Oct 13, 2020)
- Investors on record: 4

## About

Lassogen, Inc. is dedicated to the development of Lassotides™, innovative therapeutic agents designed to target challenging diseases with improved efficacy compared to traditional treatments.Founded in 2019 and headquartered in San Diego, US, Lassogen, Inc. specializes in creating novel therapeutic agents called Lassotides™ derived from unique lasso peptides. The company has successfully completed 2 deals, with the most recent being a SEED round in October 2020 in which they raised USD 4.5 mn led by Playground Ventures, alongside investors including Better Ventures and First In Capital. Mark Burk serves as both the founder and CEO of the company.Lassogen, Inc. focuses on developing and optimizing Lassotides™, which are engineered lasso peptides that function as 3D scaffolds, combining advantages of traditional antibodies and small molecules to treat diseases that remain inadequately addressed. The primary users of these therapies are healthcare providers, researchers, and patients seeking improved treatment options. Lassogen aims to expand its market reach across North America, Europe, and selected regions in Asia.Lassogen, Inc. generates revenue through strategic partnerships with pharmaceutical firms and research institutions, focusing on the commercialization of Lassotides™. These partnerships often involve collaborative agreements for research and development, leading to potential co-development or licensing deals. Revenue may also come from milestone payments and royalties associated with the commercialization of their products in various therapeutic areas, reflecting the advanced capabilities of Lassogen's innovative therapeutics.Lassogen plans to leverage the USD 4.5 mn raised in their most recent SEED funding round to further develop and launch new Lassotide™ products targeting unmet medical needs. The company is actively looking to penetrate new markets in Europe and Asia by 2023, aiming to broaden the accessibility of its innovative therapies. Recent funding will support the R&D efforts and strategic partnerships necessary for expanding Lassogen's product offerings and market presence.

## Funding rounds

- Seed, Oct 13, 2020, $4.5M — Better Ventures, Playground Ventures, Foothill Ventures, First In Capital

## Investors

- Better Ventures — Seed
- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Seed
- Foothill Ventures (https://capitalatlas.ai/funds/foothill-ventures) — Seed
- First In Capital (https://capitalatlas.ai/funds/first-in-capital) — Seed